LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Decode Genetics ehf
Headquarters:
Reykjavik, Iceland
Website:
N/A
Year Founded:
1996
Status:
Acquired
BioCentury
|
Sep 13, 2019
Company News
Sept. 12 Company Quick Takes: Atomwise in China deal; plus Ardelyx, GSK, Amarin, deCode
Read More
BioCentury
|
Sep 1, 2018
Politics, Policy & Law
Back to School 2018: A pathway to Biopharma 3.0
Back to School 2018: How external disrupters will drive biopharma to new business model
Read More
BioCentury
|
May 17, 2018
Finance
Europe’s piece of the pie
Where European life science innovators can take the lead
Read More
BioCentury
|
Jun 13, 2017
Distillery Techniques
Biomarkers
Read More
BioCentury
|
Apr 11, 2017
Distillery Techniques
Biomarkers
Read More
BioCentury
|
Oct 26, 2016
Financial News
Genomics Medicine Ireland raises $40M series A
Read More
BioCentury
|
Dec 3, 2015
Targets & Mechanisms
The two faces of LTA4H
LTA4H's pro- and anti-inflammatory effects call for inhibitor selectivity
Read More
BioCentury
|
Sep 14, 2015
Strategy
Mind melding
How Novartis and Amgen crafted a multi-asset swap to spread risk in neurology
Read More
BioCentury
|
Dec 8, 2014
Finance
Polaris hunts problems and solutions
How Polaris plans to spend new $450M hybrid fund
Read More
BioCentury
|
May 12, 2014
Tools & Techniques
Speedy clinical analysis
NextCode enables fast clinical interpretation of patient sequencing data
Read More
Items per page:
10
1 - 10 of 40